While the mutational status of KEAP1 is one of the most critical biomarkers for molecular classification and general survival time of the patients,[23] high SOX9 expression appeared to confer poor outcome in KEAP1‐mutated lung cancer patients (Figure 5L). The gene discussed is SOX9; the disease is lung cancer.